Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Humiliation tops list of mistreatment toward med students

  • Researchers examine effectiveness of blocking nerve to help with weight loss

  • Economic success drives language extinction

  • Mouse model provides window into working brain

  • Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco

  • High dietary salt may worsen multiple sclerosis symptoms

  • How Alzheimer's peptides shut down cellular powerhouses

  • Real tremors, or drug-seeking patient? New app can tell

  • Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms

  • Nucleotide change could initiate Fragile X Syndrome

  •